Advertisement
Screener

BIOATLA, INC. (BCAB) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

BioAtla, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • BioAtla, Inc. return tang equity for the quarter ending 2026-06-30 was 86.80%, a 75.58% decline year-over-year.
  • BioAtla, Inc. return tang equity for the quarter ending 2026-03-31 was 135.67%, a change of 11447.55% year-over-year.
  • BioAtla, Inc. return tang equity for the quarter ending 2025-12-31 was 164.71%, a change of 653.85% year-over-year.
  • BioAtla, Inc. return tang equity for the quarter ending 2025-09-30 was 207.15%, a change of 563.37% year-over-year.
  • BioAtla, Inc. return tang equity for fiscal 2025 was -164.71%, a change of 324.43% from fiscal 2024.
  • BioAtla, Inc. return tang equity for fiscal 2024 was -489.14%, a change of -314.44% from fiscal 2023.
  • BioAtla, Inc. return tang equity for fiscal 2023 was -174.70%, a change of -115.65% from fiscal 2022.
  • BioAtla, Inc. return tang equity for fiscal 2022 was -59.05%, a change of -13.79% from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-3086.80%-$31.45M-$36.24M
2026-03-31135.67%-$50.62M-$37.31M
2025-12-31164.71%-$59.61M-$36.19M
2025-09-30207.15%-$64.71M-$31.24M
2025-06-30355.42%-$59.52M-$16.75M
2025-03-31-11311.88%-$61.88M$547,000.00
2024-12-31-489.14%-$69.78M$14.27M
2024-09-30-356.22%-$81.82M$22.97M
2024-06-30-333.30%-$104.56M$31.37M
2024-03-31-239.83%-$119.24M$49.72M
2023-12-31-174.70%-$123.46M$70.67M
2023-09-30-131.02%-$124.08M$94.7M
2023-06-30-93.59%-$116.53M$124.52M
2023-03-31-70.12%-$109.69M$156.43M
2022-12-31-59.05%-$106.48M$180.34M
2022-09-30-71.74%-$102.33M$142.63M
2022-06-30-60.31%-$99.48M$164.95M
2022-03-31-53.12%-$100.96M$190.05M
2021-12-31-45.25%-$95.4M$210.82M
2021-09-30-38.33%-$88.41M$230.65M
2021-06-30-43.31%-$77.11M$178.02M
2021-03-31-27.03%-$52.95M$195.92M
2020-12-31-17.07%-$35.85M$209.97M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-164.71%-$59.61M$36.19M
2024-12-31-489.14%-$69.78M$14.27M
2023-12-31-174.70%-$123.46M$70.67M
2022-12-31-59.05%-$106.48M$180.34M
2021-12-31-45.25%-$95.4M$210.82M
2020-12-31-17.07%-$35.85M$209.97M
2019-12-3153.30%-$29.86M-$56.01M

Similar stocks

Stock NameCountryMarket CapPE Ratio
EXOZYMES INC. (EXOZ)United States$0.058B
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
Tevogen Inc. (TVGN)United States$0.049B
Instil Bio, Inc. (TIL)United States$0.048B-1.73
LeonaBio, Inc. (LONA)United States$0.047B-0.61
BioStem Technologies, Inc. (BSEM)United States$0.069B
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02